Health Care & Life Sciences » Biotechnology | ARCA biopharma Inc.

ARCA biopharma Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
16,756.00
15,354.00
38,802.00
21,163.00
11,752.00
6,608
Other Current Assets
169.00
134.00
114.00
282.00
547.00
169
Total Current Assets
16,925.00
15,488.00
38,916.00
21,445.00
12,299.00
6,777
Net Property, Plant & Equipment
29.00
36.00
28.00
66.00
42.00
24
Total Investments and Advances
-
-
-
2,352.00
-
-
Other Assets
130.00
608.00
630.00
766.00
24.00
24
Total Assets
17,084.00
16,132.00
39,574.00
24,629.00
12,365.00
6,825
Accounts Payable
597.00
-
-
-
-
Other Current Liabilities
905.00
1,388.00
1,504.00
2,396.00
2,070.00
Total Current Liabilities
1,502.00
1,388.00
1,504.00
2,396.00
2,070.00
Other Liabilities
1.00
3.00
-
39.00
20.00
Total Liabilities
1,503.00
1,391.00
1,504.00
2,435.00
2,090.00
Common Equity (Total)
15,581.00
14,741.00
38,070.00
22,194.00
10,275.00
Total Shareholders' Equity
15,581.00
14,741.00
38,070.00
22,194.00
10,275.00
Total Equity
15,581.00
14,741.00
38,070.00
22,194.00
10,275.00
Liabilities & Shareholders' Equity
17,084.00
16,132.00
39,574.00
24,629.00
12,365.00

About ARCA biopharma

View Profile
Address
11080 CirclePoint Road
Westminster Colorado 80020
United States
Employees -
Website http://www.arcabiopharma.com
Updated 07/08/2019
ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, GencaroTM is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications.